Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated safety, tolerability, and pharmacokinetics of BG00010 (Neublastin) in subjects with sciatica and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sciatica

Drugs mentioned

• Neublastin (BG00010) (BG00010)

Snippet

Sponsor: Biogen | Conditions: Sciatica | Phase 1 | Status: COMPLETED